[Differential Treatment of Parkinson's Disease, with Special Reference to the Possibility of Iatrogenic Disorders (author's Transl)]

Overview

Journal Arch Psychiatr Nervenkr (1970)

Specialties Neurology
Psychiatry

Date 1974 Apr 9

PMID 4836359

Authors

W Gehlen

Affiliations

Soon will be listed here.

References

Voller G, Kerstan J . [The treatment of Parkinson's syndrome with L-dopa]. Nervenarzt. 1970; 41(3):138-44. View

Schneider E, FISCHER P, Jacobi P, MAXION H . [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease]. Arch Psychiatr Nervenkr (1970). 1973; 217(1):95-112. DOI: 10.1007/BF02552835. View

Goldberg L, Whitsett T . Cardiovascular effects of levodopa. Clin Pharmacol Ther. 1971; 12(2):376-82. DOI: 10.1002/cpt1971122part2376. View

AEBERT K . [What success does L-Dopa have in the treatment of parkinsonian akinesia?]. Dtsch Med Wochenschr. 1967; 92(11):483-7. DOI: 10.1055/s-0028-1103669. View

Pletscher A, BARTHOLINI G, GEY K, Jenni A . [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa]. Schweiz Med Wochenschr. 1970; 100(19):797-804. View

PAKESCH E . [The drug-induced Parkinson's syndrome]. Wien Z Nervenheilkd Grenzgeb. 1966; 23(1):140-6. View

Martin W . Adverse reactions during treatment of Parkinson's disease with levodopa. JAMA. 1971; 216(12):1979-83. View

Godwin-Austen R, Bergmann S, Frears C . Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa. Br Med J. 1971; 4(5786):522-4. PMC: 1799802. DOI: 10.1136/bmj.4.5786.522. View

Mindham R . Psychiatric symptoms in Parkinsonism. J Neurol Neurosurg Psychiatry. 1970; 33(2):188-91. PMC: 493439. DOI: 10.1136/jnnp.33.2.188. View

10.

LAVY S, Abramsky O, Carmon A, Yaar I, Feldman S . Certain prediction on the effectiveness of L-DOPA on parkinsonism. Z Neurol. 1973; 203(4):271-8. DOI: 10.1007/BF00316184. View

11.

DEGKWITZ R . [Drug-induced Parkinson's syndrome]. Dtsch Med Wochenschr. 1972; 97(22):882. View

12.

Romer F, BETTAG W, Bock W . [L-dopa effect in Parkinson's syndrome]. Z Allgemeinmed. 1971; 47(6):281-3. View

13.

DESCHAUER A . [Experiences in the treatment of parkinsonism with KL 373 in combination with soventolette]. Arztl Wochensch. 1955; 10(30):694-6. View

14.

Voller G, Deze J, Gundlach U, Muschard F . [Problems and therapy of L-DOPA-induced dyskinesias]. Nervenarzt. 1972; 43(11):584-6. View

15.

UMBACH W, Oppel F . [Combined therapy of parkinsonism using amantadine]. Munch Med Wochenschr. 1973; 115(14):604-7. View

16.

DEGKWITZ R . [l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics]. Med Klin. 1969; 64(33):1451-6. View

17.

Walzholz U, Schonfelder H . [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study]. Nervenarzt. 1972; 43(10):531-2. View

18.

Muenter M . Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease. Neurology. 1970; 20(12):6-13. View

19.

Moccetti T, Lichtlen P . [Changes in the heart due to phenothiazines and imipramine derivatives]. Dtsch Med Wochenschr. 1971; 96(25):1089-91. DOI: 10.1055/s-0028-1108389. View

20.

Marsden C, BARRY P, Parkes J, ZILKHA K . Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. J Neurol Neurosurg Psychiatry. 1973; 36(1):10-4. PMC: 494269. DOI: 10.1136/jnnp.36.1.10. View